[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412798":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":68,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"RWTH Aachen University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"patients with schizophrenia",null,"200 patients with a DSM 5- diagnosis of schizophrenia",[13],"Genetic: Genotyping",{"label":15,"type":10,"description":16,"interventionNames":17},"healthy relatives of patients with schizophrenia","200 healthy relatives of the patients with schizophrenia",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"healthy control subjects","healthy control subjects without relatives with mental disorders",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"GENETIC","Genotyping","Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes",[19,15,9],[29],{"name":30,"affiliation":31,"role":32},"Arnim Gaebler, M.D.","Uniklinik RWTH Aachen","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+49 241 800","agaebler@ukaachen.de",[39,53,62],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"Alexianer Hospital","RECRUITING","Aachen","Northrine-Westphalia","52062","Germany","DE",{"type":48,"coordinates":49},"Point",[50,51],6.08342,50.77664,{"lat":51,"lon":50},{"facility":54,"status":41,"city":55,"state":43,"zip":56,"country":45,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"ViaNobis - Die Fachklinik","Gangelt","52538",{"type":48,"coordinates":58},[59,60],5.99802,50.99247,{"lat":60,"lon":59},{"facility":63,"status":41,"city":42,"state":10,"zip":64,"country":45,"countryCode":46,"cosmosGeoPoint":65,"geoPoint":67,"contacts":10},"University hospital RWTH Aachen","52525",{"type":48,"coordinates":66},[50,51],{"lat":51,"lon":50},{"type":32,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Arnim Gaebler","Jun.-Prof. Dr. med. Arnim Johannes Gaebler","100412798","translational-investigation-of-the-glutamatergic-and-gabaergic-system-in-schizophrenia-100412798",false,"NCT04655235","Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia","Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia - a Combined EEG-, FMRI-, Genetic, Serological and Cell Biological Study","PATIENTS\n\nInclusion Criteria:\n\n* diagnosis of schizophrenia according to DSM-5\n* aged 18 to 80\n* being mentally and contractually capable to give their consent to study participation\n\nExclusion Criteria:\n\n* pregnancy\n* structural neurological disease\n* a further psychiatric comorbidity that dominates in the clinical appearance\n\nHEALTHY PARTICIPANTS\n\nInclusion Criteria:\n\n* aged 18 to 80\n* being mentally and contractually capable to give their consent to study participation\n\nExclusion Criteria:\n\n* pregnancy\n* structural neurological disease\n* psychiatric disorder\n* for healthy controls: psychiatric disorders in the family history of first-degree relatives",true,"ALL","18 Years","80 Years",{"count":83,"type":84},600,"ESTIMATED","OBSERVATIONAL","In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.",[88],"Schizophrenia","2025-03-11",{"date":91,"type":92},"2025-03-14","ACTUAL",{"date":94,"type":92},"2021-10-01",{"date":96,"type":84},"2030-03",{"name":5,"class":6},3]